Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge

Although nivolumab is administered every two or four weeks, high programmed cell death-1 (PD-1) binding of nivolumab on T cells lasting for several months has been reported. A relationship between the PD-1 occupancy rate on T-cells and the efficacy of nivolumab is not yet fully understood. The prese...

Descripción completa

Detalles Bibliográficos
Autores principales: Nose, Taku, Funakoshi, Yohei, Suto, Hirotaka, Nagatani, Yoshiaki, Imamura, Yoshinori, Toyoda, Masanori, Kiyota, Naomi, Minami, Hironobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022082/
https://www.ncbi.nlm.nih.gov/pubmed/35463212
http://dx.doi.org/10.3892/mco.2022.2537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022082/
https://www.ncbi.nlm.nih.gov/pubmed/35463212
http://dx.doi.org/10.3892/mco.2022.2537

Ejemplares similares